BACKGROUND: We are developing a heterologous prime-boost vaccine strategy against malaria. This approach uses sequential immunization with different vectors to deliver a common preerythrocytic malaria antigen. Preliminary evidence of efficacy and safety has been previously documented in studies from an area where malaria is nonendemic. Additional safety data from an area where malaria is endemic are now required before larger-scale studies are undertaken to determine the efficacy of this vaccine strategy in the field. Other modified vaccinia virus Ankara (MVA) recombinants and prime-boost immunizations are being developed as vaccines against human immunodeficiency virus (HIV) infection, tuberculosis, and cancer, and MVA is a candidate attenuated smallpox vaccine. METHODS: Candidate vaccines against malaria were intradermally administered to 73 adults (7 of whom were HIV positive) and 22 children in Kenya. These vaccines used the attenuated fowlpox strain FP9 and the MVA recombinant for either of 2 preerythrocytic malaria antigens, multiple preerythrocytic-stage epitopes joined with the preerythrocytic-stage antigen TRAP (ME-TRAP) and the circumsporozoite protein (CS). Adverse events were recorded. RESULTS: Reactogenicity was mild. MVA caused less frequent and less severe cutaneous reaction if given after FP9 priming. Half doses reduced the frequency and the severity of systemic reactogenicity, and particular vaccine lots were associated with different reactogenicities. Unexpectedly, prior immunity to the ME-TRAP antigen appeared to be protective against local reactions after immunization. CONCLUSIONS: Where the final intention is to use MVA after FP9 priming, previous testing of MVA alone overestimates reactogenicity. These recombinant vectors appear to be safe and suitable for use in larger-scale studies of children in Africa and of HIV-positive individuals.
BACKGROUND: We are developing a heterologous prime-boost vaccine strategy against malaria. This approach uses sequential immunization with different vectors to deliver a common preerythrocytic malaria antigen. Preliminary evidence of efficacy and safety has been previously documented in studies from an area where malaria is nonendemic. Additional safety data from an area where malaria is endemic are now required before larger-scale studies are undertaken to determine the efficacy of this vaccine strategy in the field. Other modified vaccinia virus Ankara (MVA) recombinants and prime-boost immunizations are being developed as vaccines against human immunodeficiency virus (HIV) infection, tuberculosis, and cancer, and MVA is a candidate attenuated smallpox vaccine. METHODS: Candidate vaccines against malaria were intradermally administered to 73 adults (7 of whom were HIV positive) and 22 children in Kenya. These vaccines used the attenuated fowlpox strain FP9 and the MVA recombinant for either of 2 preerythrocytic malaria antigens, multiple preerythrocytic-stage epitopes joined with the preerythrocytic-stage antigen TRAP (ME-TRAP) and the circumsporozoite protein (CS). Adverse events were recorded. RESULTS: Reactogenicity was mild. MVA caused less frequent and less severe cutaneous reaction if given after FP9 priming. Half doses reduced the frequency and the severity of systemic reactogenicity, and particular vaccine lots were associated with different reactogenicities. Unexpectedly, prior immunity to the ME-TRAP antigen appeared to be protective against local reactions after immunization. CONCLUSIONS: Where the final intention is to use MVA after FP9 priming, previous testing of MVA alone overestimates reactogenicity. These recombinant vectors appear to be safe and suitable for use in larger-scale studies of children in Africa and of HIV-positive individuals.
Authors: Thomas J Scriba; Michele Tameris; Nazma Mansoor; Erica Smit; Linda van der Merwe; Fatima Isaacs; Alana Keyser; Sizulu Moyo; Nathaniel Brittain; Alison Lawrie; Sebastian Gelderbloem; Ashley Veldsman; Mark Hatherill; Anthony Hawkridge; Adrian V S Hill; Gregory D Hussey; Hassan Mahomed; Helen McShane; Willem A Hanekom Journal: Eur J Immunol Date: 2010-01 Impact factor: 5.532
Authors: Method D Segeja; Bruno P Mmbando; Misago D Seth; John P Lusingu; Martha M Lemnge Journal: BMC Infect Dis Date: 2010-03-08 Impact factor: 3.090
Authors: Tony Hawkridge; Thomas J Scriba; Sebastian Gelderbloem; Erica Smit; Michele Tameris; Sizulu Moyo; Trudie Lang; Ashley Veldsman; Mark Hatherill; Linda van der Merwe; Helen A Fletcher; Hassan Mahomed; Adrian V S Hill; Willem A Hanekom; Gregory D Hussey; Helen McShane Journal: J Infect Dis Date: 2008-08-15 Impact factor: 5.226
Authors: Edwin P Hui; Graham S Taylor; Hui Jia; Brigette B Y Ma; Stephen L Chan; Rosalie Ho; Wai-Lap Wong; Steven Wilson; Benjamin F Johnson; Ceri Edwards; Deborah D Stocken; Alan B Rickinson; Neil M Steven; Anthony T C Chan Journal: Cancer Res Date: 2013-01-24 Impact factor: 12.701
Authors: Tamara K Berthoud; Matthew Hamill; Patrick J Lillie; Lenias Hwenda; Katharine A Collins; Katie J Ewer; Anita Milicic; Hazel C Poyntz; Teresa Lambe; Helen A Fletcher; Adrian V S Hill; Sarah C Gilbert Journal: Clin Infect Dis Date: 2011-01-01 Impact factor: 20.999
Authors: Birgit Schäfer; Georg W Holzer; Alexandra Joachimsthaler; Sogue Coulibaly; Michael Schwendinger; Brian A Crowe; Thomas R Kreil; P Noel Barrett; Falko G Falkner Journal: PLoS One Date: 2011-09-09 Impact factor: 3.240
Authors: Caroline Ogwang; Muhammed Afolabi; Domtila Kimani; Ya Jankey Jagne; Susanne H Sheehy; Carly M Bliss; Christopher J A Duncan; Katharine A Collins; Miguel A Garcia Knight; Eva Kimani; Nicholas A Anagnostou; Eleanor Berrie; Sarah Moyle; Sarah C Gilbert; Alexandra J Spencer; Peninah Soipei; Jenny Mueller; Joseph Okebe; Stefano Colloca; Riccardo Cortese; Nicola K Viebig; Rachel Roberts; Katherine Gantlett; Alison M Lawrie; Alfredo Nicosia; Egeruan B Imoukhuede; Philip Bejon; Britta C Urban; Katie L Flanagan; Katie J Ewer; Roma Chilengi; Adrian V S Hill; Kalifa Bojang Journal: PLoS One Date: 2013-03-19 Impact factor: 3.240